Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension.

BACKGROUND The continuous infusion of prostacyclin has been shown to improve exercise capacity and survival in patients with primary pulmonary hypertension (PPH). Inhalation of iloprost, a stable analog of prostacyclin, might be an alternative therapy for PPH, selectively acting on the pulmonary vascular bed through ventilation-matched alveolar deposition of the drug. We investigated the short-term effects of iloprost inhalation on exercise capacity and gas exchange in patients with PPH. METHODS AND RESULTS In 11 patients with PPH, we performed 2 consecutive cardiopulmonary exercise tests before and after the inhalation of 17 microgram of iloprost. Patients had marked pulmonary hypertension (mean pulmonary artery pressure 65 mm Hg), and inhalation resulted in a decrease in pulmonary vascular resistance (1509 versus 1175 dyne. s(-1). cm(-5), P<0.05). Arterial blood gases remained unchanged (PaO(2) 69.3 versus 66.8 mm Hg; PaCO(2) 29.6 versus 28.8 mm Hg). Iloprost significantly (P<0.05) improved exercise duration (379 versus 438 seconds), peak oxygen uptake (12.8 versus 14.2 mL. kg(-1). min(-1)), VE-versus-V CO(2) slope (58 versus 51.4). CONCLUSIONS The present data show that iloprost inhalation exerts pulmonary vasodilatation and improves symptoms and exercise capacity in patients with PPH. The data also suggest that iloprost inhalation is a suitable treatment for PPH. Whether these effects are maintained during long-term treatment and are paralleled by improvement in prognosis remains to be determined.

[1]  Inda,et al.  A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .

[2]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[3]  A. Khaghani,et al.  An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. , 1997, European heart journal.

[4]  P. Ponikowski,et al.  Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. , 1997, Journal of the American College of Cardiology.

[5]  W. Seeger,et al.  Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension , 1996, Annals of Internal Medicine.

[6]  T. Bein,et al.  Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system. , 1996, Journal of cardiovascular pharmacology.

[7]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[8]  K. Wasserman.  Exercise gas exchange in heart disease , 1995 .

[9]  B. Groves,et al.  Acute Hemodynamic Effects of Iloprost in Primary (Unexplained) Pulmonary Hypertension , 1994 .

[10]  G. Pietra.  Histopathology of primary pulmonary hypertension. , 1994, Chest.

[11]  R. Casaburi,et al.  Determination of the anaerobic threshold by gas exchange: biochemical considerations, methodology and physiological effects. , 1994, Zeitschrift fur Kardiologie.

[12]  W. Seeger,et al.  Aerosolised prostacyclin in adult respiratory distress syndrome , 1993, The Lancet.

[13]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[14]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[15]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[16]  B. Groves,et al.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.

[17]  H. Palevsky,et al.  Classification of Histologic Lesions in Primary Pulmonary Hypertension Group Medial lesions Intimal lesions Medial hypertrophy Increased smooth muscle , 2005 .

[18]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[19]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[20]  G. D'Alonzo,et al.  Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. , 1987, Chest.

[21]  T. Higenbottam,et al.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). , 1987, British heart journal.

[22]  M. Packer,et al.  Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. , 1984, Journal of the American College of Cardiology.

[23]  J. S. Bower,et al.  Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. , 1984, The American review of respiratory disease.

[24]  T. Higenbottam,et al.  LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) , 1984, The Lancet.

[25]  S. Rich,et al.  Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. , 1984, The American journal of medicine.

[26]  B. Massie,et al.  Deleterious effects of hydralazine in patients with pulmonary hypertension. , 1982, The New England journal of medicine.

[27]  A. Fishman,et al.  Oxygen Utilization and Ventilation During Exercise in Patients with Chronic Cardiac Failure , 1982, Circulation.

[28]  N. Lamarra,et al.  Breath-by-breath measurement of true alveolar gas exchange. , 1981, Journal of applied physiology: respiratory, environmental and exercise physiology.

[29]  J. S. Bower,et al.  Mechanisms of gas exchange abnormality in patients with chronic obliterative pulmonary vascular disease. , 1979, The Journal of clinical investigation.